Shigeki Ohtake

Kanazawa, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 68 publications

ELTS Score and Early "Warning" Define a Two-Stage Risk Framework for Failure-Free Survival in Chronic-Phase CML.

ELTS Score and Early "Warning" Define a Two-Stage Risk Framework for Failure-Free Survival in Chronic-Phase CML.

Journal: Blood advances
Published: May 12, 2026

Treatment-Free Remission and Immune Profiling after Frontline Second-Generation TKI Therapy in CML.

Treatment-Free Remission and Immune Profiling after Frontline Second-Generation TKI Therapy in CML.

Journal: Blood advances
Published: May 05, 2026

Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs.

Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs.

Journal: Blood advances
Published: January 13, 2026

Dasatinib is superior to imatinib in adult Ph + ALL: a propensity score-matched analysis of pooled JALSG trial data.

Dasatinib is superior to imatinib in adult Ph + ALL: a propensity score-matched analysis of pooled JALSG trial data.

Journal: International journal of hematology
Published: June 06, 2025

Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study.

Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study.

Journal: Blood advances
Published: January 15, 2024

Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete molecular remission.

Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete molecular remission.

Journal: American journal of hematology
Published: October 18, 2023

Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).

Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).

Journal: International journal of hematology
Published: August 26, 2023

Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).

Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).

Journal: International journal of hematology
Published: June 25, 2023

Outcomes of transplant-eligible patients with myelodysplastic syndrome with excess blasts registered in an observational study: The JALSG-CS11-MDS-SCT.

Outcomes of transplant-eligible patients with myelodysplastic syndrome with excess blasts registered in an observational study: The JALSG-CS11-MDS-SCT.

Journal: Annals of hematology
Published: May 12, 2023

High-risk Combinations of Additional Chromosomal Abnormalities in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: JALSG Ph+ALL TKI-SCT Study.

High-risk Combinations of Additional Chromosomal Abnormalities in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: JALSG Ph+ALL TKI-SCT Study.

Journal: HemaSphere
Published: January 25, 2023

Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms.

Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms.

Journal: Blood advances
Published: December 19, 2022

Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial.

Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial.

Journal: International journal of hematology
Published: December 10, 2021
Showing 1-12 of 68

Last Updated: 09/26/2026